Share this page:

A Dose Escalation Safety Study of Locally-Delivered (Intra-Arterial) Gemcitabine in Unresectable Adenocarcinoma of the Pancreas

Phase: IV
Status: Not Recruiting

Patients diagnosed with unresectable pancreatic cancer who may or may not have had prior chemotherapy or radiation therapy may be eligible to enroll in this dose escalation study to determine the maximum tolerated dose of gemcitabine to be delivered locally to the pancreatic tumors using the RenovoCath R120 catheter. Although this drug and device are FDA approved, this trial is testing the two in combination for safety and efficacy.

Principal Investigator

Jiali Li, MD

Sponsor

RenovoRx, Inc

NCT Number

NCT02237157

Contact

Kathy Miller, Clinical Research Coordinator
Taft Center for Clinical Research
650-962-4562
Kathryn_Miller@elcaminohealth.org

For more information about this clinical trial, including trial status, eligibility and full trial listing, visit www.clinicaltrials.gov.

You may also be interested in...

Visitor Screener

Visitor Restrictions

A visitor policy is in effect due to more restrictive measures being taken throughout the Bay Area.
HealthPerks Banner

Sign Up for HealthPerks

It's a free membership program with a monthly newsletter, event registrations, and more.
Find a doctor who will fit you well.

Find a Doctor

Use our directory to find a doctor with an office near our Mountain View or Los Gatos campus.